Cargando…

Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study

Background The IF-DIABETE system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-D...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouf, Siham, Rbiai, Najwa, Baibai, Kaoutar, Berrich, Jamal, Bouchentouf, Toumi, Rahmoun, Mohammed, Abda, Naima, Latrech, Hanane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872867/
https://www.ncbi.nlm.nih.gov/pubmed/33585132
http://dx.doi.org/10.7759/cureus.12646
_version_ 1783649272204361728
author Rouf, Siham
Rbiai, Najwa
Baibai, Kaoutar
Berrich, Jamal
Bouchentouf, Toumi
Rahmoun, Mohammed
Abda, Naima
Latrech, Hanane
author_facet Rouf, Siham
Rbiai, Najwa
Baibai, Kaoutar
Berrich, Jamal
Bouchentouf, Toumi
Rahmoun, Mohammed
Abda, Naima
Latrech, Hanane
author_sort Rouf, Siham
collection PubMed
description Background The IF-DIABETE system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-DIABETE system in improving clinical and metabolic outcomes in individuals with type 1 diabetes. Methods This is a prospective nonrandomized single-arm pilot study. Our patients used the IF-DIABETE smartphone application as a novel bolus calculator. Over six months period of the study, the primary outcome considered was hemoglobin glycated (HbA1c), and we identified hypoglycemic events, body mass index (BMI), and the frequency of blood glucose measurements as secondary outcomes. Results Twenty-one patients with type 1 diabetes were enrolled. The average age was 21 ± 3 years. Over a six months’ period of the study, the mean HbA1c level decreased from 8.3 ± 0.8% to 7.0 ± 0.5 % with a reduction in mild hypoglycemic events’ frequency from 5 ± 3 to 1 ± 0.7 episodes/3 months. We did not observe any change in BMI and the frequency of the blood glucose testing improved from 2 ± 0.5 to 5 ± 1 tests per day. Conclusion The IF-DIABETE system was safe and effective to support individuals who have type 1 diabetes to improve their metabolic control. At six months, patients were able to improve their glycemic control without increasing the risk of hypoglycemic events.
format Online
Article
Text
id pubmed-7872867
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-78728672021-02-11 Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study Rouf, Siham Rbiai, Najwa Baibai, Kaoutar Berrich, Jamal Bouchentouf, Toumi Rahmoun, Mohammed Abda, Naima Latrech, Hanane Cureus Endocrinology/Diabetes/Metabolism Background The IF-DIABETE system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-DIABETE system in improving clinical and metabolic outcomes in individuals with type 1 diabetes. Methods This is a prospective nonrandomized single-arm pilot study. Our patients used the IF-DIABETE smartphone application as a novel bolus calculator. Over six months period of the study, the primary outcome considered was hemoglobin glycated (HbA1c), and we identified hypoglycemic events, body mass index (BMI), and the frequency of blood glucose measurements as secondary outcomes. Results Twenty-one patients with type 1 diabetes were enrolled. The average age was 21 ± 3 years. Over a six months’ period of the study, the mean HbA1c level decreased from 8.3 ± 0.8% to 7.0 ± 0.5 % with a reduction in mild hypoglycemic events’ frequency from 5 ± 3 to 1 ± 0.7 episodes/3 months. We did not observe any change in BMI and the frequency of the blood glucose testing improved from 2 ± 0.5 to 5 ± 1 tests per day. Conclusion The IF-DIABETE system was safe and effective to support individuals who have type 1 diabetes to improve their metabolic control. At six months, patients were able to improve their glycemic control without increasing the risk of hypoglycemic events. Cureus 2021-01-12 /pmc/articles/PMC7872867/ /pubmed/33585132 http://dx.doi.org/10.7759/cureus.12646 Text en Copyright © 2021, Rouf et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Rouf, Siham
Rbiai, Najwa
Baibai, Kaoutar
Berrich, Jamal
Bouchentouf, Toumi
Rahmoun, Mohammed
Abda, Naima
Latrech, Hanane
Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study
title Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study
title_full Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study
title_fullStr Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study
title_full_unstemmed Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study
title_short Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study
title_sort feasibility and efficiency of a novel bolus calculator (if-diabete) for patients with type 1 diabetes: a nonrandomized single-arm pilot study
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872867/
https://www.ncbi.nlm.nih.gov/pubmed/33585132
http://dx.doi.org/10.7759/cureus.12646
work_keys_str_mv AT roufsiham feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy
AT rbiainajwa feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy
AT baibaikaoutar feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy
AT berrichjamal feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy
AT bouchentouftoumi feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy
AT rahmounmohammed feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy
AT abdanaima feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy
AT latrechhanane feasibilityandefficiencyofanovelboluscalculatorifdiabeteforpatientswithtype1diabetesanonrandomizedsinglearmpilotstudy